It has been reported that miR-223 enhances breast cancer invasion by inhibiting the expression of myocyte enhancer factor 2C (Mef2c) and increases the progression of gastric cancer by specifically targeting RhoB (168, 169). Here, MEF2C is linked to breast cancer.